Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05988021 · ClinicalTrials.gov registry record · Phase 1
A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168
A Phase 1 study of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT05988021 is a Phase 1 study of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis that has completed, run by Amgen. The registered enrollment target is 16 participants, below the 37-participant average among 3 other Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05988021, a Phase 1 study of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this clinical trial is to evaluate the effect of a high-fat, high-calorie meal on the pharmacokinetic (PK) profile of CCX168, following oral administration of a single dose of 30 mg CCX168 to healthy volunteers.
Conditions Studied
Interventions
- DRUG CCX168
Study Locations (1)
Arizona
- Celerion - Tempe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2015-12-03 |
| Est. Completion | 2016-05-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05988021
The ClinicalTrials.gov registry entry for NCT05988021 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 37-participant average among 3 other Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis trials with a reported enrollment target (57% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis appearing as the primary indexed condition, and to 1 intervention - of which CCX168 is the first listed.
NCT05988021 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT05988021 about?
NCT05988021 is a clinical study titled "A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168". The primary objective of this clinical trial is to evaluate the effect of a high-fat, high-calorie meal on the pharmacokinetic (PK) profile of CCX168, following oral administration of a single dose of 30 mg CCX168 to healthy volunteers.
What is the current status of trial NCT05988021?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2015-12-03. Estimated completion is 2016-05-25.
What conditions does trial NCT05988021 study?
This clinical trial studies the following conditions: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis.
What interventions are being tested in trial NCT05988021?
The interventions under investigation include: CCX168 (DRUG).
Who is sponsoring clinical trial NCT05988021?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05988021 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)
ACTIVE NOT RECRUITING · Phase 1
-
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
ACTIVE NOT RECRUITING · Phase 1
-
A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.